Invest in a sector with a high degree of innovation that contributes to new and better treatments for patients

The biotechnology sector is a central driving force for innovation in the healthcare sector, with the development of new treatments for serious and chronic diseases. The demand for more effective treatment solutions is structurally driven by demographic changes, increasing disease burden, and significant unmet medical needs. At the same time, biotechnology companies serve as an important source of external innovation for large international pharmaceutical companies, among other things through partnerships and acquisitions, contributing to long-term value creation in the sector.

The fund primarily invests in companies that have achieved clinical proof of concept, have documented technology or are in the commercial phase. This helps to reduce technological and clinical risk and provides a clearer basis for value creation in biotechnology, pharmaceuticals, diagnostics, AI in healthcare, drug manufacturing, and other areas of healthcare with a high degree of innovation. The fund may also invest in companies in earlier development stages, where thorough analysis indicates that the risk is manageable, and where we see significant potential for changed value understanding over time. At the same time, the sector is more volatile than the broad stock market, providing attractive investment opportunities for active managers with thorough analysis, selective exposure, and disciplined risk management.

The actively managed equity fund typically invests in 40–60 companies within the global biotechnology ecosystem, across geography and market capitalization. The fund seeks companies with clear value drivers, solid growth prospects, and attractive risk and return profiles.

, focusing on technology, clinical data, regulatory frameworks, and commercial potential. The fund particularly focuses on companies in late clinical and commercial phases but selectively invests in earlier phases when the risk and return profile is deemed attractive. An important part of the strategy is exposure to small and medium-sized biotechnology companies, where innovation and value creation are often most evident.